PLEXION NS

PLEXION NS is an FDA drug label for the active ingredient SULFACETAMIDE SODIUM manufactured by Eckson Labs, LLC administered by TOPICAL. This page reproduces the FDA-approved indications and usage, dosage, contraindications, warnings, and adverse reactions exactly as published in the drug label. Data source: openFDA (U.S. FDA), label effective 20220210.

Generic: SULFACETAMIDE SODIUM

Manufacturer: Eckson Labs, LLC

Product Type: HUMAN PRESCRIPTION DRUG

Route: TOPICAL

Dosage Form:

NDC: 44118-712

Application:

Effective: 20220210

Indications & Usage

INDICATIONS: This product is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff).

Dosage & Administration

DOSAGE AND ADMINISTRATION: Shake well before using. Apply to wet hair and massage vigorously into scalp. Rinse thoroughly. For best results, use at least twice a week or as directed by a doctor. Avoid contact with eyes or mucous membranes. Do not use on an infant less than 2 months of age.

Contraindications

CONTRAINDICATIONS: This product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. This product is not to be used by patients with kidney disease.

Warnings

WARNINGS: Sulfonamides are known to cause Stevens-Johnson syndrome in hypersensitive individuals. Stevens-Johnson syndrome also has been reported following the use of sodium sulfacetamide topically. Cases of drug-induced systemic lupus erythematosus from topical sulfacetamide also have been reported. In one of these cases, there was a fatal outcome. KEEP OUT OF REACH OF CHILDREN.

Adverse Reactions

ADVERSE REACTIONS: Reports of irritation and hypersensitivity to sodium sulfacetamide are uncommon. The following adverse reactions, reported after administration of sterile ophthalmic sodium sulfacetamide, are noteworthy: instances of Stevens-Johnson syndrome and instances of local hypersensitivity which progressed to a syndrome resembling systemic lupus erythematosus; in one case a fatal outcome was reported (see WARNINGS).

More from same ingredient

Klaron

Bausch Health US, LLC

SULFACETAMIDE SODIUM

KMM Pharmaceuticals, LLC

Sulfacetamide Sodium

Asclemed USA, Inc.

Sulfacetamide Sodium

Proficient Rx LP

Sulfacetamide Sodium

Asclemed USA, Inc.

Sulfacetamide Sodium

Padagis Israel Pharmaceuticals Ltd

Sulfacetamide Sodium

Bausch & Lomb Incorporated